home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408e.zip
/
M9480870.TXT
< prev
next >
Wrap
Text File
|
1994-09-05
|
2KB
|
38 lines
Document 0870
DOCN M9480870
TI Serum markers of immune activation in HIV-associated pulmonary
tuberculosis.
DT 9410
AU Wallis R; Helfand M; Vjecha M; Whalen C; Mugerwa R; Okwera A; Ellner J;
Case Western Reserve University, Cleveland, Ohio.
SO Abstr Gen Meet Am Soc Microbiol. 1994;94:190 (abstract no. U-99). Unique
Identifier : AIDSLINE ASM94/94313075
AB Survival is shortened in HIV-infected patients with tuberculosis (TB) as
compared to CD4-matched HIV-infected controls. We measured serum markers
of immune activation in HIV-infected patients beginning treatment for
pulmonary TB in Kampala, Uganda. Patients were followed for 16 months or
until death. Initial levels of neopterin, beta 2 microglobulin, and
receptors to TNF alpha and IL-2 were significantly higher in those who
died: TABULAR DATA, SEE ABSTRACT VOLUME. These parameters did not
correlate with X-ray findings as to extent location, or cavitary nature
of disease. The markers did not change significantly during the first 2
months of therapy in either survivors or non-survivors, not did they
predict radiographic or microbiologic response to therapy or relapse.
This suggests that mortality in HIV-associated tuberculosis may be more
closely related to stage and/or progression of HIV disease rather than
to progressive tuberculosis. Inasmuch as serum levels of receptors for
IL-2 and TNF alpha parallel production of these cytokines in vivo, and
both cytokines promote HIV expression in vitro, increased production of
cytokines may provide mechanism for acceleration of HIV disease in
patients with tuberculosis.
DE AIDS-Related Opportunistic Infections/*BLOOD/IMMUNOLOGY/MORTALITY
Biological Markers/BLOOD Biopterin/*ANALOGS & DERIVATIVES/BLOOD
Comparative Study Human Predictive Value of Tests Prognosis
Receptors, Interleukin-2/*ANALYSIS Receptors, Tumor Necrosis
Factor/*ANALYSIS Survival Rate Tuberculosis,
Pulmonary/*BLOOD/COMPLICATIONS/MORTALITY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).